Literature DB >> 9415611

Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases.

C Díaz-Cascajo1, W Weyers, L Borrego, J B Iñarrea, S Borghi.   

Abstract

Dermatofibrosarcoma protuberans (DFSP) with fibrosarcoma (FS)-like areas (DFSP-FS) is a peculiar neoplasm that combines microscopic findings of DFSP and FS. Because of the scarce number of cases published, tumor prognosis remains controversial. The clinical histories and the histologic material of 27 cases of DFSP were reviewed. Four of them showed fibrosarcomatous areas. Follow-up data, ranging from 12 to 125 months, were obtained in all four cases. Two patients had repeated local recurrences. One patient developed pulmonary metastases and died of disease 49 months after diagnosis. In the other two patients, no recurrences or metastases were detected at 12 and 70 months after local excision, respectively. Progressive increase of FS areas, cellular density, cellular atypia, and mitotic activity were observed during the recurrences. All cases showed diffuse positive immunostaining for CD34 in DFSP areas. Three cases were also CD34-positive in FS areas. Based on a careful review of the literature and our personal experience, we conclude that DFSP-FS is a rare variant of DFSP with a higher rate of local recurrences and more distant metastases than typical DFSP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415611     DOI: 10.1097/00000372-199712000-00002

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  7 in total

1.  COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans.

Authors:  J Wang; Y Morimitsu; S Okamoto; M Hisaoka; T Ishida; W Sheng; H Hashimoto
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas.

Authors:  Zoltan Szollosi; Beata Scholtz; Kristof Egervari; Zoltan Nemes
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

3.  CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

Authors:  Grant Eilers; Jeffrey T Czaplinski; Mark Mayeda; Nacef Bahri; Derrick Tao; Meijun Zhu; Jason L Hornick; Neal I Lindeman; Ewa Sicinska; Andrew J Wagner; Jonathan A Fletcher; Adrian Mariño-Enriquez
Journal:  Mol Cancer Ther       Date:  2015-04-07       Impact factor: 6.261

4.  Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases.

Authors:  Z Szollosi; Z Nemes
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

5.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Authors:  Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

Review 6.  Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations.

Authors:  Cyril Fisher
Journal:  Virchows Arch       Date:  2009-04-28       Impact factor: 4.064

7.  Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.

Authors:  Piotr Rutkowski; Agnieszka Wozniak; Tomasz Switaj
Journal:  Sarcoma       Date:  2011-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.